Post Conference Perspectives: Trilaciclib, a New Option for Chemotherapy-Induced Myelosuppression

Ralph Boccia, MD and Jim Schwartz, RPh provide key insights into the recent FDA approval of trilaciclib and discuss its impact on the treatment landscape for extensive-stage small cell lung cancer.

EP. 1: Impact of Myelosuppression in Extensive-Stage SCLC

May 6th 2021

Ralph Boccia, MD, discusses myelosuppression with chemotherapy and highlights its impact on treatment outcomes and patient quality of life.

EP. 2: Trilaciclib in SCLC: Mechanism of Action and Dosage

May 6th 2021

Jim Schwartz, RPh, provides key insights into the recent approval of trilaciclib and discusses how CDK4/6 inhibition potentially improves response to cytotoxic chemotherapy by protecting patients from myelosuppression.

EP. 3: Registrational Trials for the FDA Approval of Trilaciclib

May 13th 2021

An expert in the management of small cell lung cancer gives an in-depth review of the study design, safety, and efficacy of the clinical trials that led to the FDA approval of trilaciclib for chemotherapy-induced myelosuppression.

EP. 4: Potential Adverse Effects of Trilaciclib

May 13th 2021

Ralph Boccia, MD, and Jim Schwartz, RPh, build a discussion on the potential adverse effects of trilaciclib, including fatigue, hypocalcemia, hypokalemia, injection site reactions, pneumonitis, and interstitial lung disease.

EP. 5: Impact of Trilaciclib on the Treatment Landscape

May 13th 2021

Ralph Boccia, MD, and Jim Schwartz, RPh, discuss the overall impact the approval for trilaciclib will have on patients’ treatment outcomes, health care expenses, and quality of life.